Johnson & Johnson (JNJ) Reports Q4 2025 Revenue of $24.6 Billion, Pharma Business Exceeds $60 Billion for First Time
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy JNJ?
Source: seekingalpha
- Significant Revenue Growth: Johnson & Johnson reported worldwide sales of $24.6 billion for Q4 2025, reflecting a 7.1% increase, with the pharmaceutical segment exceeding $60 billion for the first time, indicating strong growth potential in the pharmaceutical sector.
- Investment in R&D and Acquisitions: The company invested over $32 billion in R&D and M&A in 2025, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics, aiming to drive future growth through innovation.
- Strong Product Performance: In Oncology, DARZALEX and CARVYKTI achieved sales of over $14 billion and 63.2% growth, respectively, demonstrating Johnson & Johnson's competitiveness and market share expansion in high-growth markets.
- Optimistic Future Outlook: Johnson & Johnson anticipates operational sales growth between 5.7% and 6.7% for 2026, targeting $100 billion in annual sales, reflecting the company's confidence and strategic planning for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 225.340
Low
190.00
Averages
218.50
High
240.00
Current: 225.340
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Priority Review for IMAAVY® (Nipocalimab-AAHU) as a Potential First Treatment for Warm Autoimmune Hemolytic Anemia (WAIHA)
FDA Grants Priority Review: The FDA has granted priority review for a potential first approved treatment for people living with Warm Autoimmune Hemolytic Anemia (WAIHA).
Significance of Treatment: This treatment could provide a new therapeutic option for patients suffering from this condition, which affects the immune system and red blood cells.
See More
FDA Greenlights CAPLYTA® (LUMATEPERONE) SNDA Backed by Strong New Evidence of Lower Relapse Risk in Schizophrenia
FDA Approval: The FDA has approved Caplyta® (lumateperone) for the treatment of schizophrenia.
New Data Support: The approval is backed by robust new data demonstrating a reduced risk of relapse in patients with schizophrenia.
See More
Johnson & Johnson to Present at Bernstein's Strategic Decisions Conference
- Conference Schedule: Johnson & Johnson will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with management engaging in a Fireside Chat at 11:00 a.m. Eastern Time to outline future strategic directions.
- Webcast Availability: The audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website, ensuring that investors can stay updated with the company's latest developments and enhancing transparency.
- Replay Arrangement: An archived edition of the session will be available later that day, with the audio webcast replay expected to be accessible approximately 48 hours after the live event, allowing investors who missed the live session to catch up.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, ensuring timely information dissemination and communication, further enhancing interaction between the company and its investors.
See More
Johnson & Johnson Leverages AI to Enhance Drug Development Efficiency
- Reduced Drug Development Time: Johnson & Johnson has halved the time required to generate new leads for drug development using artificial intelligence, indicating a significant efficiency boost in drug research that is expected to accelerate the market entry of new medications.
- Clinical Report Preparation Efficiency: The time required for traditional clinical trial report preparation has been slashed from 700-900 hours to about 15 minutes, a change that not only drastically reduces labor costs but also enables quicker responses to regulatory requirements, enhancing compliance.
- AI in Manufacturing: J&J is applying AI technology to optimize manufacturing processes, allowing for the timely and temperature-appropriate addition of solvents, thereby improving production efficiency and product quality, which further strengthens market competitiveness.
- Employee Skill Expansion: J&J emphasizes that AI technology is not replacing employees but rather expanding the skill sets of its existing IT workforce, with around 4,000 IT employees transitioning to higher-level skill applications, thereby enhancing the company's overall technological capabilities.
See More
FDA Grants Priority Review for IMAAVY in Autoimmune Hemolytic Anemia
- FDA Priority Review: The U.S. FDA has granted Priority Review to IMAAVY (nipocalimab-aahu), confirming the urgent need for treatment options in warm autoimmune hemolytic anemia (wAIHA), with an expected review timeline of approximately six months, potentially accelerating market access.
- Clinical Trial Results: In the pivotal Phase 2/3 ENERGY study, IMAAVY demonstrated a significant durable hemoglobin response and notable fatigue improvement compared to placebo, indicating its potential in treating wAIHA effectively.
- Therapeutic Innovation: IMAAVY targets the neonatal Fc receptor (FcRn) to effectively reduce circulating immunoglobulin G (IgG) and autoantibodies while preserving key immune functions, providing a differentiated option compared to existing immunosuppressive therapies and addressing a critical unmet medical need.
- Market Outlook: wAIHA is a rare and life-threatening condition affecting approximately 1-3 individuals per 100,000 annually, and the introduction of IMAAVY could provide new treatment options for this niche market, significantly improving patients' quality of life.
See More
FDA Grants Priority Review for IMAAVY in Autoimmune Hemolytic Anemia
- FDA Priority Review: The U.S. FDA has granted Priority Review for the supplemental Biologics License Application (sBLA) of IMAAVY (nipocalimab-aahu), indicating the drug's potential significance in treating warm autoimmune hemolytic anemia (wAIHA), with a review timeline shortened to approximately six months, potentially accelerating its market introduction.
- Clinical Trial Results: In the pivotal Phase 2/3 ENERGY study, IMAAVY demonstrated significant efficacy, with treated patients achieving durable hemoglobin levels of ≥10 g/dL and an increase of ≥2 g/dL, alongside notable fatigue improvement, indicating the drug's potential to enhance patient quality of life.
- Treatment Need: wAIHA is a severe condition where current treatment options largely consist of unapproved immunosuppressive therapies that fail to address the underlying cause, and the development of IMAAVY aims to fill this treatment gap, addressing the urgent need for effective therapies among patients.
- Strategic Implications: The Priority Review of IMAAVY not only highlights its innovative potential in the field of autoimmune diseases but may also lay the groundwork for Johnson & Johnson's further advancements in immunology therapies, enhancing its competitive position in the market.
See More
FDA Approves Priority Review for IMAAVY® (Nipocalimab-AAHU) as a Potential First Treatment for Warm Autoimmune Hemolytic Anemia (WAIHA)
FDA Grants Priority Review: The FDA has granted priority review for a potential first approved treatment for people living with Warm Autoimmune Hemolytic Anemia (WAIHA).
Significance of Treatment: This treatment could provide a new therapeutic option for patients suffering from this condition, which affects the immune system and red blood cells.
See More
FDA Greenlights CAPLYTA® (LUMATEPERONE) SNDA Backed by Strong New Evidence of Lower Relapse Risk in Schizophrenia
FDA Approval: The FDA has approved Caplyta® (lumateperone) for the treatment of schizophrenia.
New Data Support: The approval is backed by robust new data demonstrating a reduced risk of relapse in patients with schizophrenia.
See More
Johnson & Johnson to Present at Bernstein's Strategic Decisions Conference
- Conference Schedule: Johnson & Johnson will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with management engaging in a Fireside Chat at 11:00 a.m. Eastern Time to outline future strategic directions.
- Webcast Availability: The audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website, ensuring that investors can stay updated with the company's latest developments and enhancing transparency.
- Replay Arrangement: An archived edition of the session will be available later that day, with the audio webcast replay expected to be accessible approximately 48 hours after the live event, allowing investors who missed the live session to catch up.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, ensuring timely information dissemination and communication, further enhancing interaction between the company and its investors.
See More
Johnson & Johnson Leverages AI to Enhance Drug Development Efficiency
- Reduced Drug Development Time: Johnson & Johnson has halved the time required to generate new leads for drug development using artificial intelligence, indicating a significant efficiency boost in drug research that is expected to accelerate the market entry of new medications.
- Clinical Report Preparation Efficiency: The time required for traditional clinical trial report preparation has been slashed from 700-900 hours to about 15 minutes, a change that not only drastically reduces labor costs but also enables quicker responses to regulatory requirements, enhancing compliance.
- AI in Manufacturing: J&J is applying AI technology to optimize manufacturing processes, allowing for the timely and temperature-appropriate addition of solvents, thereby improving production efficiency and product quality, which further strengthens market competitiveness.
- Employee Skill Expansion: J&J emphasizes that AI technology is not replacing employees but rather expanding the skill sets of its existing IT workforce, with around 4,000 IT employees transitioning to higher-level skill applications, thereby enhancing the company's overall technological capabilities.
See More
FDA Grants Priority Review for IMAAVY in Autoimmune Hemolytic Anemia
- FDA Priority Review: The U.S. FDA has granted Priority Review to IMAAVY (nipocalimab-aahu), confirming the urgent need for treatment options in warm autoimmune hemolytic anemia (wAIHA), with an expected review timeline of approximately six months, potentially accelerating market access.
- Clinical Trial Results: In the pivotal Phase 2/3 ENERGY study, IMAAVY demonstrated a significant durable hemoglobin response and notable fatigue improvement compared to placebo, indicating its potential in treating wAIHA effectively.
- Therapeutic Innovation: IMAAVY targets the neonatal Fc receptor (FcRn) to effectively reduce circulating immunoglobulin G (IgG) and autoantibodies while preserving key immune functions, providing a differentiated option compared to existing immunosuppressive therapies and addressing a critical unmet medical need.
- Market Outlook: wAIHA is a rare and life-threatening condition affecting approximately 1-3 individuals per 100,000 annually, and the introduction of IMAAVY could provide new treatment options for this niche market, significantly improving patients' quality of life.
See More
FDA Grants Priority Review for IMAAVY in Autoimmune Hemolytic Anemia
- FDA Priority Review: The U.S. FDA has granted Priority Review for the supplemental Biologics License Application (sBLA) of IMAAVY (nipocalimab-aahu), indicating the drug's potential significance in treating warm autoimmune hemolytic anemia (wAIHA), with a review timeline shortened to approximately six months, potentially accelerating its market introduction.
- Clinical Trial Results: In the pivotal Phase 2/3 ENERGY study, IMAAVY demonstrated significant efficacy, with treated patients achieving durable hemoglobin levels of ≥10 g/dL and an increase of ≥2 g/dL, alongside notable fatigue improvement, indicating the drug's potential to enhance patient quality of life.
- Treatment Need: wAIHA is a severe condition where current treatment options largely consist of unapproved immunosuppressive therapies that fail to address the underlying cause, and the development of IMAAVY aims to fill this treatment gap, addressing the urgent need for effective therapies among patients.
- Strategic Implications: The Priority Review of IMAAVY not only highlights its innovative potential in the field of autoimmune diseases but may also lay the groundwork for Johnson & Johnson's further advancements in immunology therapies, enhancing its competitive position in the market.
See More
